- Home
- GBR vs VIVS Comparison
GBR vs VIVS Comparison
Compare GBR & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBR | VIVS |
|---|---|---|
| Founded | 1978 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.8M |
| IPO Year | 1995 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GBR | VIVS |
|---|---|---|
| Price | $0.74 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.8K | ★ 619.2K |
| Earning Date | 05-14-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $155,000.00 | ★ $4,603,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 6.16 | ★ 8.82 |
| 52 Week Low | $0.62 | $0.26 |
| 52 Week High | $1.31 | $4.98 |
Technical Indicators
Market Signals| Indicator | GBR | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 33.99 |
| Support Level | N/A | $0.27 |
| Resistance Level | N/A | $0.58 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 16.83 |
Price Performance
Historical ComparisonAbout GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.